Journal of Commercial Biotechnology — November 2011 issue now available

The November 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Journal of Commercial Biotechnology Vol 17, Issue 4 (2011)

Exciting changes
Yali Friedman
Full details at the Journal of Commercial Biotechnology

New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?
Aarthi Rao
Biotechnology companies can play an important role in advancing technologies for global health. Initiatives such as Genzyme’s Humanitarian Assistance for Neglected Diseases and Alnylam’s Intellectual Property (IP) contributions to the Pool for Open Innovation against Neglected Tropical Diseases show a commitment to helping produce badly needed health technologies, but unmet needs for new drugs, vaccines and diagnostics for diseases affecting developing countries remain…
Full details at the Journal of Commercial Biotechnology

Biotechnology commercialisation in universities of developing countries: A review of the University of Ibadan, Nigeria
Chimdiya Julian Onyeka
The British colonial administration established the University of Ibadan (UI) in 1948 as an extension of the University College London and it became Nigeria’s first full-fledged and premier university in 1962. The university comprises 13 faculties and a distance learning programme. Among the university’s faculties is one for Science, one for Technology and another for Agriculture and Forestry…
Full details at the Journal of Commercial Biotechnology

Innovation in R&D: Using design thinking to develop new models of inventiveness, productivity and collaboration
Tad Simons, Arvind Gupta, Mary Buchanan
By adapting insights and methodologies from design thinking, a modern scientific R&D organization may have the potential to increase the speed, inventiveness and vitality of their output and become an explosive engine of growth. Modern design consultancies face the challenge of producing original, creative work for their clients on project after project, and have thus developed several strategies and behaviors to produce innovative content repeatedly at a fast pace…
Full details at the Journal of Commercial Biotechnology

The strength of pharmaceutical IPRs vis-à-vis foreign direct investment in clinical research: Preliminary findings
Meir Perez Pugatch, Rachel Chu
This article examines the effect of the intellectual property (IP) environment in developing countries on the level of foreign direct investment (FDI) and technology transfer occurring in the biopharmaceutical field in these countries. In particular, it considers the correlation between the strength of IP protection in several developing countries (using the Pharmaceutical IP Index) and the number of clinical trials taking place in these countries (as a proxy of biomedical FDI)…
Full details at the Journal of Commercial Biotechnology

Some considerations for the implementation of disposable technology and single-use systems in biopharmaceuticals
Tim Sandle, Madhu Raju Saghee
This article, written from an industry perspective, examines the current trend towards the implementation of single-use disposable technologies in the biopharmaceutical and biotechnology sectors. Single-use technologies are generally sterile, plastic disposable items implemented to replace traditional pharmaceutical processing items that require recycling, cleaning and in-house sterilisation…
Full details at the Journal of Commercial Biotechnology

Catalyzing capital for Canada’s life sciences industry
Joseph Tucker, Justin Chakma, Paul WM Fedak, Massimo Cimini
Canada’s biotech sector ranks within the top five globally, but its life sciences venture capital (VC) industry is among the worlds weakest. This makes for an interesting case study in understanding the disconnect between low levels of VC and a healthy innovation ecosystem in terms of R&D spending, skilled workforce and enterprise support…
Full details at the Journal of Commercial Biotechnology

Academic entrepreneurship, entrepreneurial universities and biotechnology
Arlen D Meyers, Sarika Pruthi
There are various definitions of an entrepreneurial university, yet there is a lack of agreement about its core components. This article defines the five key characteristics of an entrepreneurial university based on examples of successful bio-clusters in the United States and Europe, and suggests an agenda for stakeholders…
Full details at the Journal of Commercial Biotechnology

Patent strategies for life sciences companies to navigate the changing patent landscape
David J Dykeman, Danielle T Abramson
As a result of the global recession that began in 2008, life sciences companies face a groundswell of new business and regulatory pressures that includes health care and patent reform, increased pricing pressures, and diluted markets. Bringing new products from discovery to market is becoming more expensive and unpredictable…
Full details at the Journal of Commercial Biotechnology

FDA at BIO 2011 – Weighing a hefty mission: Where is the balance?
Suzanne Levy
The mission of the Food and Drug Administration (FDA) is to promote public health by ensuring the safety and quality of food and medical products sold in the United States. At this year’s annual Biotechnology Industry Organization (BIO) convention, significant discussion revolved around the appropriate interpretation and execution of that mission…
Full details at the Journal of Commercial Biotechnology

For more information, see the Journal of Commercial Biotechnology

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

October 28, 2011

28 Oct 2011

New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?

Biotechnology companies can play an important role in advancing technologies for global health. Initiatives such as Genzyme's Humanitarian Assistance for Neglected Diseases and Alnylam's Intellectual Property (IP) contributions to the Pool for Open Innovation against Neglected Tropical Diseases show a commitment to helping produce badly needed health technologies, but unmet needs for new drugs, vaccines and diagnostics for diseases affecting developing countries remain. Controlling malaria, visceral leishmaniasis and other infectious diseases that cause significant morbidity and mortality requires new and improved technological tools. Biotechnology companies’ expertise in biologics, point-of-care diagnostics and preclinical drug development is invaluable in this field, which is short of innovators.

Most firms, however, face disincentives in conducting R&D for global health since product markets are small and uncertain, the scientific problems are tough to solve, and few existing financing or policy mechanisms compensate for the risk. Product Development Partnerships and other non-profit initiatives have taken on much of the work in this area through grant financing and have often partnered with industry, but biotechnology firms could play a greater role. New policy and financing mechanisms that can balance the investment equation and encourage biotechnology and pharmaceutical firms to include global health diseases in their R&D portfolios could unleash important advances in global health technologies.

Full details at the Journal of Commercial Biotechnology

0 Likes

/2 Tweets/in Biotechnology Industry News, General Biotechnology

October 28, 2011

28 Oct 2011

Exciting changes

Full details at the Journal of Commercial Biotechnology

0 Likes

/2 Tweets/in Biotechnology Industry News, General Biotechnology

October 26, 2011

26 Oct 2011

Where in the United States are drugs invented?

Following on the heels of my post on Globalization in the Pharmaceutical Industry, it is also useful to examine the distribution of inventorship across the United States. The stakes aren’t quite as high here — public health and national security don’t come in to play — but there still are important implications for economic development.

Using the same methodology, assigning relative inventorship of the patents from each year’s approved drugs from 2000 through 2010 (source: www.DrugPatentWatch.com), I focused on US inventors and examined the distribution by state.

1: New Jersey and California lead the nation

There aren’t too many surprises at the top of the list; one would expect New Jersey, California, and Massachusetts to top the list. Going further down the list shows strong activity in states that might not get the attention they deserve as leaders of pharmaceutical innovation.

2: Some states show surprising volatility

While the patenting activity in states like New Jersey and California seems relatively stable year-over-year and fairly tracks the graph’s overall trend, there is great volatility in other states. Massachusettts and Ohio, for example, show sharp spikes in absolute and relative terms. This activity merits additional investigation, and is potentially an opportunity for regional economic development authorities to identify and support the activities enabling the spikes.

You can also get more detailed information on the complete set of drug inventors and where they live in my United States Drug Patent Inventor Report. A Global Drug Patent Inventor Report and other Individual Country Drug Patent Inventor Reports are also available.

What do you think of the findings? Are you surprised? Do you disagree? Sound off in the comments.

0 Comments/

0 Likes

/24 Tweets/in General Biotechnology

October 25, 2011

25 Oct 2011

Pocket Biotechnology Industry Primer and Glossary

I’ve just published the Pocket Biotechnology Industry Primer and Glossary as an ebook. This book, which was previously only available as a printed book, is now available in digital format, which means greater convenience and a significant price reduction. This primer and glossary presents a broad, accessible, and comprehensive overview of the biotechnology industry and the factors shaping it, enabling readers to understand and profit from the expanding influence of biotechnology.

For more information, see Building Biotechnology, the leading textbook in biotechnology management programs, from which this primer was derived.